Maintenance Notice (10:30 PM January 4 - 8:00 AM January 5, 2025 UTC): This website is scheduled to be unavailable due to maintenance. We appreciate your patience and understanding.
Published TCIMAIL newest issue No.197 | Notice of Discontinuing the Use of Password-Protected Compressed Files | Various analytical charts can be searched on each product detail page and Product Document Search (The kinds of analytical charts differ by product)
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 69655-05-6 | Product Number: D3066
2',3'-Dideoxyinosine
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- ddI
- 9-(2,3-Dideoxy-β-D-ribofuranosyl)-6-oxopurine
- Didanosine
- 9-(2,3-Dideoxy-β-D-ribofuranosyl)hypoxanthine
Product Documents:
| Size | Unit Price | Same Day | 2-3 Business Days | Other Lead Time |
Shipping Information
|
|---|---|---|---|---|---|
| 100MG |
₩66,600
|
2 | 0 | Contact Us | |
| 500MG |
₩220,200
|
4 | 0 | Contact Us |
* Please contact our distributor of SEJIN CI Co., Ltd.
if you would like to purchase TCI products. The above prices do not include freight cost, customs charge and other charges to the destination. SEJIN CI Co., Ltd. (Phone: 02-2655-2480 / email:
sales@sejinci.co.kr)
* The storage conditions are subject to change without notice.
* The storage conditions are subject to change without notice.
Supplemental Product Information:
This product is a sample for RUO (research use only). Do not use this product for any purpose other than testing and research.
| Product Number | D3066 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__1__0H__1__2N__4O__3 = 236.23 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
| Store Under Inert Gas | Store under inert gas |
| Condition to Avoid | Hygroscopic |
| Packaging and Container | 100MG-Glass Bottle with Plastic Insert (View image), 500MG-Glass Bottle with Plastic Insert (View image) |
| CAS RN | 69655-05-6 |
| Reaxys Registry Number | 3619529 |
| PubChem Substance ID | 87559876 |
| SDBS (AIST Spectral DB) | 52174 |
| Merck Index (14) | 3098 |
| MDL Number | MFCD00077728 |
Specifications
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Neutralization titration) | min. 98.0 % |
| Specific rotation [a]20/D | -26.0 to -30.0 deg(C=0.34, H2O) |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 182 °C |
| Specific Rotation | -28° (C=0.34,H2O) |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H373 : May cause damage to organs through prolonged or repeated exposure. H341 : Suspected of causing genetic defects. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P260 : Do not breathe dust/ fume/ gas/ mist/ vapors/ spray. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P405 : Store locked up. |
Related Laws:
| RTECS# | NM7460700 |
Transport Information:
| H.S.code* | 2940.00-000 |
Application
Didanosine (ddI): A Nucleoside Reverse Transcriptase Inhibitor
2',3'-Dideoxyadenosine (ddA) [D3065] and didanosine (ddI) are nucleoside reverse transcriptase inhibitors. ddA is a synthetic nucleoside analogue of the naturally occurring nucleoside 2’-deoxyadenosine in which the 3'-hydroxyl group is replaced by hydrogen. Intracellularly, ddA and ddI are converted by cellular enzymes to the active metabolite, ddA- 5'-triphosphate. The triphosphate inhibits the activity of viral reverse transcriptase both by competing with the natural substrate, 2’-deoxyadenosine-5'-triphosphate, and by its incorporation into viral DNA causing termination of viral DNA chain. (The product is for research purpose only.)
References
- Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection.
- Didanosine. An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease
- Didanosine: an updated review of its use in HIV infection
- Didanosine enteric-coated capsule: current role in patients with HIV-1 infection
- Twenty-Six Years of Anti-HIV Drug Discovery: Where Do We Stand and Where Do We Go?
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.